Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KS-20260
- Development stage
- Preclinical
- Lead developer
- AIGEN Sciences
- Modality
- Small Molecules
01
Overview
KS-20260 is a potent small molecule inhibitor of Iron Regulatory Protein 2 (IRP2), developed by AIGEN Sciences using their AI-driven AIGEN InSight platform. IRP2 is a key regulator of intracellular iron homeostasis and is frequently overexpressed in colorectal cancer (CRC), where it contributes to tumor progression. KS-20260 was optimized from earlier IRP2 inhibitors to provide enhanced potency. Research indicates that KS-20260 exhibits synergistic antitumor efficacy when combined with the EGFR inhibitor osimertinib in CRC models. This combination therapy disrupts cell-cycle progression by downregulating key regulators such as CDK1, AURKB, CENPF, and E2F8, leading to significant reductions in tumor volume and weight in vivo.
Beyond the preview
Go deeper on KS-20260.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KS-20260.